Why Globus Medical’s latest earnings beat matters now
Globus Medical (GMED) just cleared Wall Street forecasts again, posting quarterly profit and sales above consensus for a fourth straight period. Yet the share price has cooled, leaving a visible gap between results and valuation.
Over the past few months, Globus Medical’s share price has been choppy, with a 1 day move down of 5.86% and a 7 day share price return down 4.13%. This comes even though the 1 year total shareholder return sits at 29.24% and the 3 year total shareholder return at 66.10%. As a result, recent momentum looks cooler than the longer term record and helps explain why an earnings beat is not yet feeding into a stronger valuation.
Spot potential Globus Medical lookalikes by running your own screen across 33 high quality undervalued stocks that pair resilient cash generation with balance sheets that support continued product investment.Globus Medical keeps posting solid earnings while the share price cools. The business looks strong. The open question is whether the current tag at about $78 already reflects that strength or still falls short.
Most Popular Narrative: 23% Undervalued
Globus Medical last closed at $78.05, while the most followed narrative framework pegs fair value near $100.92 using a 7.52% discount rate. That gap puts the focus squarely on whether margin progress and platform breadth can support a higher valuation than the market is currently assigning.
The main thing that has to go right is continued execution on margin expansion from manufacturing efficiencies and M&A synergies, while keeping growth on track in robotics, trauma, international spine and neuromodulation despite volatility in Enabling Technologies and Nevro revenue.
The current valuation implies investors are not fully crediting the combination of mid 30s adjusted EBITDA margins, progress toward low 70s adjusted gross margins, EPS guidance upgrades and ongoing share repurchases in the Globus Medical share price.
See why 21 investors see Globus Medical as 23% undervalued.
Result: Fair Value of $100.92 (UNDERVALUED)
Still, the narrative can crack if Enabling Technologies and Nevro stay weak for longer, or if hospital pricing pressure reduces Globus Medical procedure volumes.
Find out about the key risks to this Globus Medical narrative.
Next Steps
Sentiment on Globus Medical is clearly upbeat, so do not just take this narrative at face value. Move quickly, look through the key numbers, and pressure test the optimistic angles by reviewing the 5 key rewards.
Looking for more investment ideas beyond Globus Medical?
If Globus Medical has sharpened your interest, do not stop at a single ticker. Broaden your watchlist with focused stock ideas built from hard numbers.
- Target resilient compounding potential by scanning a curated 33 high quality undervalued stocks that pairs quality fundamentals with prices the market may be underappreciating.
- Prioritise sleep-at-night stability through a 29 resilient stocks with low risk scores that filters for balance sheets and risk scores designed to limit nasty surprises.
- Get ahead of the crowd by reviewing a 19 high quality undiscovered gems built to surface under-the-radar businesses with strong underlying financials before they are widely followed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com